Inefficiency of cynarin as therapeutic regimen in familial type ii hyperlipoproteinaemia

Heckers, H.; Dittmar, Kurt E.J.; Schmahl, F. W.; Huth, K

doi:10.1016/0021-9150(77)90107-1

Cited by 15 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, the data may disagree with those of Rodriguez et al (2002), who found that repeated (twice a day for 7 consecutive days) oral administration of aqueous artichoke leaf extract (100, 200, and 400 mg/kg) to rats produced no significant differences in cholesterol, TG and phospholipids. The data are also not in agreement with (46) who reported insufficiency of cynarin, the active ingredient of artichoke (250 mg before meals either once or 3 times daily) as a therapeutic regimen in patients with familial type 2 hyperlipoproteinemia. The mean serum cholesterol and triglyceride concentrations in patients with Type II hyperlipoproteinemia had not significantly changed within 3 months, neither with 250 mg nor 750 mg Cynarin daily.…”

Section: Liver Function Parameterscontrasting

confidence: 99%

Protective potential of Cynara scolymus extract in thioacetamide model of hepatic injury in rats

El-Deberky

Rizk

Elsayd

et al. 2021

View full text Add to dashboard Cite

Hepatic injury is a worldwide health problem. This study aimed to evaluate the possible hepatoprotective potential of Artichoke (Cynara scolymus) extract (CSE) in albino rats using the thioacetamide (TAA) a model of liver injury. Acclimatized 42 rats were divided randomly into seven groups, each consists of six rats, and subjected to different treatments. Hepatic injury model was induced by administration of TAA at a dose of 100 mg per kg, intraperitoneally, twice weekly for 8 weeks (+ve control); test groups rats received CSE at doses of 100 or 200 mg/kg BW, orally, daily for 8 weeks adjunct with TAA; standard group rats received Silymarin at a dose of 100 mg per kg, orally, daily for 8 weeks adjunct with TAA; other 2 groups of rats received only CSE at the same dose levels; while -ve control rats received only the vehicles. Blood and liver tissue samples were collected at the end of the experimental course for different assessments. Results revealed that CSE exhibited dose-dependent hepatoprotection indicated by nearly normalized parameters, including enzymatic liver function parameters (AST, ALT, GGT & ALP with potential % of 94.06, 86.96, 85.93, 64.85, respectively, after large dose when standardized by Silymarin); non-enzymatic parameters (total protein, albumin, globulins, total bilirubin, conjugated bilirubin, unconjugated bilirubin, TAGs, Cholesterol, HDL, LDL & VLDL with potential % of 83.42, 85.9, 83.44, 98.1, 77.41, 91.5, 97.51, 97.46, 81.41, 88.52 & 89.4, respectively, after large dose when standardized by Silymarin). The underlying mechanism of the observed hepatoprotection of CSE was attributed to impeding the oxidative stress-mediated by TAA, indicated by reduced hepatocyte lipid peroxidation product MDA (95.96 % of Silymarin), and improved antioxidative enzymes in liver homogenate, namely, GPx, Catalase & SOD with potentials of 95.44, 87.02 & 81.48 % of Silymarin, respectively. Macroscopic and microscopic pathological pictures were supportive to the biochemical findings, where the pathological lesions caused by TAA as congestion and dilatation of central and portal veins with perivascular fibrous connective tissue proliferation admixed with few mononuclear leukocytes plus necrotic hepatocytes and hyperplastic biliary epithelium, were ameliorated dose-dependently when CSE was administered together with TAA. The present study's data may suggest CSE as a natural source for promising hepatoprotective and antioxidant drug preparations.

show abstract

Section: Liver Function Parameterscontrasting

confidence: 99%

Protective potential of Cynara scolymus extract in thioacetamide model of hepatic injury in rats

El-Deberky

Rizk

Elsayd

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Nonetheless, all the studies, except one, demonstrated statistically significant improvements in cholesterol and triglycerides levels. As a matter of fact, Heckers [52] administrated daily doses of 250 and 750 mg synthesis cynarin preparations for three months in 17 outpatients affected by familial type IIa or IIb hypercholesterolemia without observing any significant improvements in cholesterol and triglycerides levels, and came to the conclusion that cynarin was relatively ineffective as a therapeutic regimen in hyperlipemia. After the Polish investigator Wojcicki and collaborators had conducted studies with cynarin in the rat, they studied the influence of this compound, and then of artichoke extracts, in men of different ages affected by primitive or secondary hypercholesterolemia.…”

Section: Action On Lipid Metabolismmentioning

confidence: 99%

Health-promoting properties of artichoke in preventing cardiovascular disease by its lipidic and glycemic-reducing action

Rondanelli

Monteferrario

Perna

et al. 2015

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

The artichoke, Cynara scolymus, is one of the most ancient plants grown in the world, and its extracts, obtained from different parts of the plant (leaves, fruits and roots), have been used as medicaments from time immemorial. The pharmacological and therapeutic effects of the artichoke on the liver had already been well known in the 17th century. Modern studies started in the last century confirmed the stimulating properties of artichoke extracts on the liver and gallbladder. The ensuing wave of research was initially focused on the patent liver-stimulating, diuretic and choleretic effects exerted by artichoke preparations on both animals and man, then discovering such other therapeutic properties as the hypolipemizing activity, antioxidant activity and hypoglycemizing activity. This review enumerates the most significant studies that have highlighted these therapeutic properties. Complementary medicine information needs to be incorporated into clinical practice and patient and professional education, in addition to adequate education about proper nutrition. Awareness of the widespread use of complementary and alternative medicine by people with metabolic disorders is crucial for healthcare professionals in order to prevent cardiovascular disease.

show abstract

“…The intervention failed to produce any significant changes in cholesterol or triglyceride concentrations after 3 months of treatment [177]. None of the studies reported any significant adverse events or laboratory test abnormalities as a result of ALE treatment.…”

Section: Artichoke Leaf Extractmentioning

confidence: 56%

Dietary Supplements for Cholesterol Management

Almandoz

2015

Contemporary Endocrinology

View full text Add to dashboard Cite

Inefficiency of cynarin as therapeutic regimen in familial type ii hyperlipoproteinaemia

Cited by 15 publications

References 2 publications

Protective potential of Cynara scolymus extract in thioacetamide model of hepatic injury in rats

Protective potential of Cynara scolymus extract in thioacetamide model of hepatic injury in rats

Health-promoting properties of artichoke in preventing cardiovascular disease by its lipidic and glycemic-reducing action

Dietary Supplements for Cholesterol Management

Contact Info

Product

Resources

About